Core Viewpoint - Clearmind Medicine Inc. has entered into a development agreement with Polyrizon Ltd. to enhance the bioavailability and clinical advancement of its lead compound MEAI for addiction-related and other CNS disorders [1][2][3] Group 1: Collaboration Details - The agreement involves the application of Polyrizon's proprietary intranasal hydrogel technology to develop an optimized formulation of Clearmind's MEAI [2][3] - The collaboration aims to leverage the advantages of intranasal delivery for CNS-targeted therapeutics, which include enhanced nasal residence time, targeted delivery, and bypassing first-pass metabolism [3][5] Group 2: Company Insights - Clearmind is focused on discovering and developing novel neuroplastogen-derived therapeutics to address major under-treated health issues, including addiction and mental health disorders [1][6] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as warranted [6] Group 3: Technology Overview - Polyrizon specializes in developing innovative medical device hydrogels for nasal delivery, which can provide a barrier against viruses and allergens [7] - Their proprietary Capture and Contain™ hydrogel technology aims to improve bioadhesion and retention at the nasal deposition site for drug delivery [7]

Core Viewpoint - Polyrizon Ltd. has entered into a development agreement with Clearmind Medicine Inc. to leverage Polyrizon's intranasal delivery platform for the clinical development of Clearmind's drug candidate MEAI, aimed at treating addiction-related and other CNS conditions [1][2][3] Group 1: Collaboration Details - The collaboration aims to advance an intranasal formulation of MEAI to support Clearmind's future clinical development programs [2] - Polyrizon's proprietary intranasal technology is designed to enable targeted and efficient delivery of drugs, potentially offering significant value in Clearmind's clinical pathway [3] Group 2: Polyrizon's Technology - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [4] - The company's Capture and Contain TM hydrogel technology is designed to enhance bioadhesion and prolong retention at the nasal site for drug delivery [4][6] Group 3: Clearmind's Focus - Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel psychedelic-derived therapeutics to address underserved health issues, including alcohol use disorder [7] - The company holds a portfolio of nineteen patent families, including 31 granted patents, and aims to expand its intellectual property [8]

The Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted EBITDA Raanana, Israel, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the signing of a non-binding Memorandum of Understanding (MOU) with Arrow Aviation Ltd. (" ...

Core Insights - Polyrizon Ltd. has initiated a key usability study for its lead product candidate, NASARIX™, aimed at confirming alignment with FDA requirements and supporting clinical development [1][2] Group 1: Product Development - NASARIX™ is an innovative intranasal allergy blocker designed for broad consumer use, representing a significant advancement in Polyrizon's development roadmap [1][2] - The usability study is intended to de-risk downstream regulatory review and facilitate a streamlined path toward clinical trials [2][3] Group 2: Regulatory Milestones - Successful completion of the usability program will provide essential regulatory evidence for NASARIX™'s readiness for clinical evaluation, with trials expected to commence in Q3 2026 [3][4] - The study underscores the company's commitment to FDA-aligned development, patient safety, and user-centered solutions [4] Group 3: Company Overview - Polyrizon specializes in developing innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [4] - The proprietary Capture and Contain™ hydrogel technology aims to function as a "biological mask" in the nasal cavity, with ongoing development focused on enhancing bioadhesion and retention [4]

Core Insights - Polyrizon Ltd. is committed to advancing its core intranasal medical pipeline while exploring strategic investment opportunities in sectors such as aviation, AI, and defense [1][2][3] - The company is focusing on high-potential sectors for initial investment efforts, while continuing to develop its medical devices, including products like PL-14 and PL-16 [2][3] - Polyrizon's Board of Directors has approved selective investments aimed at generating near-term revenues and enhancing financial stability, leveraging the company's strong cash position and debt-free balance sheet [3] Company Overview - Polyrizon is a development-stage biotech company specializing in innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens [4] - The proprietary Capture and Contain TM hydrogel technology is designed to function as a "biological mask" in the nasal cavity, with ongoing development to improve bioadhesion and drug delivery [4]

As part of the branding process, Polyrizon conducted comprehensive trademark screening across the U.S. and European markets Raanana, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has completed the branding process for its PL-14 allergy blocker, which will be marketed under the brand name NASARIX™. NASARIX™ is based on Polyriz ...

Core Insights - Polyrizon Ltd. announced positive results from a pre-clinical study evaluating its PL-14 Allergy Blocker formulation, demonstrating its effectiveness in blocking allergens compared to hydroxypropyl methylcellulose (HPMC) [1][5]. Study Findings - The study utilized a validated in-vitro Transwell permeability system to assess PL-14's ability to inhibit the transfer of Der p 1, a significant house dust mite allergen associated with allergic rhinitis and asthma [2]. - PL-14 significantly reduced allergen transfer at all time points compared to HPMC, with statistical significance (p-values ≤ 0.0042) observed at 1, 2, 4, 6, and 24 hours [3][9]. - At 1 hour, PL-14 showed a mean allergen concentration of approximately 20.6 ng, while HPMC had a concentration of about 1354.4 ng. By 24 hours, HPMC's concentration rose to around 5201.2 ng, indicating limited barrier function [9]. Product Development - The results support the continued advancement of PL-14 as a preventive approach for allergic rhinitis by reducing allergen penetration through a synthetic surface [6]. - Polyrizon is advancing its preclinical development program and plans to support future clinical studies to establish PL-14's regulatory pathway and clinical benefits for allergy prevention [6]. Company Overview - Polyrizon is a development-stage biotechnology company focused on innovative medical device hydrogels delivered as nasal sprays, creating a barrier against viruses and allergens [7]. - The company's proprietary Capture and Contain TM hydrogel technology aims to function as a "biological mask" in the nasal cavity, with ongoing development to enhance bioadhesion and retention for drug delivery [7].

Raanana, Israel, Jan. 02, 2026 (GLOBE NEWSWIRE) -- As the 2025-2026 flu season intensifies across the United States, a mutated strain of influenza A is driving most cases, sparking concerns about a potentially tough winter ahead. According to the latest CDC estimates (as of late December 2025), flu has already caused at least 4.6 million illnesses, 49,000 hospitalizations, and 1,900 deaths nationwide. Flu activity is rising sharply, with outpatient visits for influenza-like illness well above baseline in ma ...

Core Viewpoint - Polyrizon Ltd. is advancing its core medical pipeline while exploring investment opportunities in revenue-generating assets to enhance shareholder value [1][3]. Product Development - The company is committed to its core medical device activities, focusing on the development of products such as PL-14 (allergy blocker), PL-16 (viral blocker), and the Trap & Target platform for intranasal drug delivery [2][3]. Strategic Initiatives - The Board of Directors has authorized the exploration of investments in assets expected to generate revenues, aiming to utilize the company's resources efficiently for growth and long-term shareholder value [3]. Technology Overview - Polyrizon specializes in innovative medical device hydrogels delivered as nasal sprays, which create a barrier against viruses and allergens in the nasal cavity [4]. - The proprietary Capture and Contain TM hydrogel technology is designed to function as a "biological mask" and is being further developed for enhanced bioadhesion and drug delivery [4].

Core Insights - Polyrizon Ltd. has submitted a Pre-Request for Designation (Pre-RFD) to the FDA for its PL-16 Viral Blocker, which has shown over 90% efficacy in protecting cells against viruses [1][2][7] - The PL-16 product is designed to create a physical barrier in the nasal cavity to reduce exposure to airborne respiratory viruses, addressing a significant public health challenge during the flu season [3][4][8] Product Overview - PL-16 is a metered-dose intranasal spray that forms a muco-adhesive hydrogel layer, mechanically reducing contact between airborne particles and the nasal epithelium [4][10] - The product is intended for local use only, with no systemic exposure or pharmacological activity [4] Supporting Evidence - The Pre-RFD submission is backed by in-vitro studies demonstrating that PL-16 preserves cell viability against influenza A and human coronavirus by preventing viral access [7] - Studies confirm that PL-16 acts purely as a mechanical barrier, with viruses remaining infective after being recovered from the hydrogel [7] Market Opportunity - The global nasal spray market was valued at USD 29.83 billion in 2024 and is projected to grow to USD 58.90 billion by 2032, with a CAGR of 8.9% [6] - Seasonal respiratory infections represent a recurring global market with significant economic impact due to lost productivity [6][8] Strategic Context - The PL-16 program is part of Polyrizon's broader strategy to develop non-medicated intranasal solutions, building on its Capture and Contain technology platform [5] - The company aims to address multiple respiratory indications through scalable, drug-free nasal technologies [5] Next Steps - Following feedback from the FDA on the Pre-RFD, Polyrizon will align on the next development steps for PL-16 and continue advancing its intranasal platform [9]